奥沙利铂联合表柔比星介入治疗原发性肝癌的效果及不良反应

Effect and adverse reaction of oxaliplatin combined with epirubicin in the treatment of primary liver cancer

目的探讨奥沙利铂联合表柔比星介入治疗原发性肝癌的效果及不良反应。方法选取2014-01-01至2016-01-01日临沂市中心医院收治的50例中晚期原发性肝癌患者,随机分成观察组和对照组,25例/组。对照组应用奥沙利铂介入治疗,观察组联合应用奥沙利铂和表柔比星介入治疗。比较两组治疗总有效率、不良反应发生率及1年生存率。结果观察组治疗总有效率高于对照组,不良反应总发生率低于对照组(P<0.05)。随访1年后,观察组生存率高于对照组(P<0.05)。结论奥沙利铂联合表柔比星介入治疗原发性肝癌安全有效。

Objective To discuss the effect and adverse reaction of oxaliplatin combined with epirubicin in the treatment of primary liver cancer.Methods 50 cases of middle and advanced primary liver cancer treated in Linyi Central Hospital from 2014-01-01 to 2016-01-01 were selected as the research subjects,and randomly divided into observation group and control group,25 cases/group.The control group was treated with oxaliplatin intervention.The observation group combined with oxaliplatin combined with epirubicin for interventional therapy.The total effective rate of treatment,the incidence of adverse reactions and the 1 year survival rate were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the total incidence of adverse reactions was lower than that of the control group(P<0.05).After 1 years of follow-up,the survival rate of the observation group was higher than that of the control group(P<0.05).Conclusion Oxaliplatin combined with epirubicin in the treatment of primary liver cancer is safe and effective.